Mayne Pharma (MAYNF) 1.5800 $MAYNF Mayne Pharma
Post# of 273254
Posted On: 09/25/2016 1:05:27 AM
Mayne Pharma (MAYNF) 1.5800 $MAYNF
Mayne Pharma Acquires Rights to a Portfolio of Dermatology Foam Products Including Fabior(R) and Sorilux(R)
BusinessWire - Thu Aug 18, 4:54AM CDT
--Fabior(R) and Sorilux(R) are complementary dermatology assets to Doryx(R) and will be marketed through Mayne Pharma's established Specialty Brands Division
GSK: 43.42 (-0.16)
Overview Of The Pharmaceutical Market in Australia 2015
M2 - Thu Sep 24, 4:31AM CDT
Research and Markets (http://www.researchandmarkets.com/research/pzlvkm/the) has announced the addition of the "The Pharmaceutical Market: Australia" report to their offering. The country's health expenditure will continue to increase with the increasingly ageing population and the need for the government to subsidise more drugs to treat chronic, non-communicable disease. Such a rise in expenditure will attract pharmaceutical firms despite the low growth potential in the developed market. However, given the poor fiscal outlook in the general economy, we believe such a generous healthcare system will be unsustainable over the long term and the country will continue look at cost-cutting measures, negatively affecting the earnings of pharmaceutical firms. Risk/Reward Rating: In The Q11 Asia Pacific Pharmaceutical and Healthcare Risk/Reward Ratings (RRRs), while Australia's overall RRR score remains 66.2, its ranking has improved from third to second out of the 18 key markets in the region due to the decline in South Korea's RRR. Australia's affluent and increasingly ageing population, coupled with its proper legal framework, will continue to attract pharmaceutical firms to the country. However, profit growth will be limited given that it is a developed market. Competitive Landscape: The competitive landscape section provides comparative company analyses and rankings by US$ sales and % share of total sales - for the total pharmaceutical sector, as well as the OTC, generics, and distribution sub-sectors. Key Topics Covered: 1. SWOT 2. Political 3. Economic 4. Business Environment 5. Industry Forecast 6. Pharmaceutical Market Forecast 7. Healthcare Market Forecast 8. Prescription Drug Market Forecast 9. Patented Drug Market Forecast 10. Generic Drug Market Forecast 11. OTC Medicine Market Forecast 12. Pharmaceutical Trade Forecast 13. Other Healthcare Data 14. Key Risks To The Forecast Scenario 15. Macroeconomic Forecasts 16. Economic Analysis 17. Chinese Reform Efforts To Weigh On Export Growth 18. Consumption Growth To Slow Further 19. Residential Investment To Fall Short 20. Industry Risk Reward Ratings 21. Asia Pacific Risk/Reward Index 22. Australia Risk/Reward Index 23. Rewards 24. Risks 25. Market Overview 26. Industry Trends And Developments 27. Epidemiology 28. Regulatory Development 29. Regulatory Regime 30. OTC Switching Climate 31. Regional Regulatory Harmonisation 32. Recent Developments 33. Intellectual Property Issues 34. Trade Agreements Companies Mentioned - Alphapharm - Australian Pharmaceutical Industries - CSL - GlaxoSmithKline - Herron Pharmaceuticals - Mayne Pharma Group - Merck & Co - Sanofi - Sigma For more information visit http://www.researchandmarkets.com/research/pzlvkm/the
MRK: 62.96 (-0.06), GSK: 43.42 (-0.16)
HedgePath Pharmaceuticals To Receive $2.5 Million in Funding From Mayne Pharma
PR Newswire - Mon May 18, 8:00AM CDT
HedgePath Pharmaceuticals, Inc., (OTCQB: HPPI) a clinical stage biopharmaceutical company that discovers, develops and plans to commercialize innovative therapeutics for patients with cancer, announced today that it has entered into a definitive agreement with an affiliate of Mayne Pharma Group Limited (ASX: MYX) under which Mayne Pharma will invest $2.5 million in HPPI in a private common stock and warrant financing. The closing of the financing is expected to occur within five business days.
Onychomycosis (Tinea Unguium) Therapeutics Pipeline Review 2015 - Analysis of 13 Companies & 15 Drug Profiles
M2 - Mon Mar 02, 6:39AM CST
Research and Markets (http://www.researchandmarkets.com/research/49c2b8/onychomycosis) has announced the addition of the "Onychomycosis (Tinea Unguium) - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Onychomycosis (Tinea Unguium), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Onychomycosis (Tinea Unguium) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Onychomycosis (Tinea Unguium) - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Onychomycosis (Tinea Unguium) pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Involved in Therapeutics Development - Actavis plc - Anacor Pharmaceuticals, Inc. - Eisai Co., Ltd. - Evolva SA - Helix BioMedix, Inc. - Mayne Pharma Group Limited - Meiji Seika Pharma Co., Ltd. - Moberg Pharma AB - NAL Pharmaceuticals Ltd. - Nihon Nohyaku Co., Ltd. - Novabiotics Ltd - Nuvo Research Inc. - Viamet Pharmaceuticals, Inc. Drug Profiles - albaconazole - AN-2718 - E-1224 - ELS-160 - EV-086 - HB-1275 - itraconazole - luliconazole - ME-1111 - NAL-3216 - NP-213 - Small Molecules for Fungal Infections - terbinafine - terbinafine - VT-1161 For more information visit http://www.researchandmarkets.com/research/49...chomycosis
ANAC: 99.06 (-0.14)
Onychomycosis Therapeutics Pipeline Market H1 2015 Review Report Available at RnRMarketResearch.com
PRWeb - Sat Feb 14, 1:30AM CST
The report "Onychomycosis (Tinea Unguium) - Pipeline Review, H1 2015″ provides comprehensive information on the therapeutic development for Onychomycosis (Tinea Unguium). Onychomycosis (Tinea Unguium) is a fungal illness of the nails. It is the most common nail disease in adults. It is spread through direct contact with the yeast. Onychomycosis is caused by thickened nail, ragged nail, unsightly nail and pain in the nail. The report strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Complete report is available @ http://www.rnrmarketresearch.com/onychomycosi...eport.html .
ANAC: 99.06 (-0.14)
Mayne Pharma Acquires Rights to a Portfolio of Dermatology Foam Products Including Fabior(R) and Sorilux(R)
BusinessWire - Thu Aug 18, 4:54AM CDT
--Fabior(R) and Sorilux(R) are complementary dermatology assets to Doryx(R) and will be marketed through Mayne Pharma's established Specialty Brands Division
GSK: 43.42 (-0.16)
Overview Of The Pharmaceutical Market in Australia 2015
M2 - Thu Sep 24, 4:31AM CDT
Research and Markets (http://www.researchandmarkets.com/research/pzlvkm/the) has announced the addition of the "The Pharmaceutical Market: Australia" report to their offering. The country's health expenditure will continue to increase with the increasingly ageing population and the need for the government to subsidise more drugs to treat chronic, non-communicable disease. Such a rise in expenditure will attract pharmaceutical firms despite the low growth potential in the developed market. However, given the poor fiscal outlook in the general economy, we believe such a generous healthcare system will be unsustainable over the long term and the country will continue look at cost-cutting measures, negatively affecting the earnings of pharmaceutical firms. Risk/Reward Rating: In The Q11 Asia Pacific Pharmaceutical and Healthcare Risk/Reward Ratings (RRRs), while Australia's overall RRR score remains 66.2, its ranking has improved from third to second out of the 18 key markets in the region due to the decline in South Korea's RRR. Australia's affluent and increasingly ageing population, coupled with its proper legal framework, will continue to attract pharmaceutical firms to the country. However, profit growth will be limited given that it is a developed market. Competitive Landscape: The competitive landscape section provides comparative company analyses and rankings by US$ sales and % share of total sales - for the total pharmaceutical sector, as well as the OTC, generics, and distribution sub-sectors. Key Topics Covered: 1. SWOT 2. Political 3. Economic 4. Business Environment 5. Industry Forecast 6. Pharmaceutical Market Forecast 7. Healthcare Market Forecast 8. Prescription Drug Market Forecast 9. Patented Drug Market Forecast 10. Generic Drug Market Forecast 11. OTC Medicine Market Forecast 12. Pharmaceutical Trade Forecast 13. Other Healthcare Data 14. Key Risks To The Forecast Scenario 15. Macroeconomic Forecasts 16. Economic Analysis 17. Chinese Reform Efforts To Weigh On Export Growth 18. Consumption Growth To Slow Further 19. Residential Investment To Fall Short 20. Industry Risk Reward Ratings 21. Asia Pacific Risk/Reward Index 22. Australia Risk/Reward Index 23. Rewards 24. Risks 25. Market Overview 26. Industry Trends And Developments 27. Epidemiology 28. Regulatory Development 29. Regulatory Regime 30. OTC Switching Climate 31. Regional Regulatory Harmonisation 32. Recent Developments 33. Intellectual Property Issues 34. Trade Agreements Companies Mentioned - Alphapharm - Australian Pharmaceutical Industries - CSL - GlaxoSmithKline - Herron Pharmaceuticals - Mayne Pharma Group - Merck & Co - Sanofi - Sigma For more information visit http://www.researchandmarkets.com/research/pzlvkm/the
MRK: 62.96 (-0.06), GSK: 43.42 (-0.16)
HedgePath Pharmaceuticals To Receive $2.5 Million in Funding From Mayne Pharma
PR Newswire - Mon May 18, 8:00AM CDT
HedgePath Pharmaceuticals, Inc., (OTCQB: HPPI) a clinical stage biopharmaceutical company that discovers, develops and plans to commercialize innovative therapeutics for patients with cancer, announced today that it has entered into a definitive agreement with an affiliate of Mayne Pharma Group Limited (ASX: MYX) under which Mayne Pharma will invest $2.5 million in HPPI in a private common stock and warrant financing. The closing of the financing is expected to occur within five business days.
Onychomycosis (Tinea Unguium) Therapeutics Pipeline Review 2015 - Analysis of 13 Companies & 15 Drug Profiles
M2 - Mon Mar 02, 6:39AM CST
Research and Markets (http://www.researchandmarkets.com/research/49c2b8/onychomycosis) has announced the addition of the "Onychomycosis (Tinea Unguium) - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Onychomycosis (Tinea Unguium), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Onychomycosis (Tinea Unguium) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Onychomycosis (Tinea Unguium) - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Onychomycosis (Tinea Unguium) pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Involved in Therapeutics Development - Actavis plc - Anacor Pharmaceuticals, Inc. - Eisai Co., Ltd. - Evolva SA - Helix BioMedix, Inc. - Mayne Pharma Group Limited - Meiji Seika Pharma Co., Ltd. - Moberg Pharma AB - NAL Pharmaceuticals Ltd. - Nihon Nohyaku Co., Ltd. - Novabiotics Ltd - Nuvo Research Inc. - Viamet Pharmaceuticals, Inc. Drug Profiles - albaconazole - AN-2718 - E-1224 - ELS-160 - EV-086 - HB-1275 - itraconazole - luliconazole - ME-1111 - NAL-3216 - NP-213 - Small Molecules for Fungal Infections - terbinafine - terbinafine - VT-1161 For more information visit http://www.researchandmarkets.com/research/49...chomycosis
ANAC: 99.06 (-0.14)
Onychomycosis Therapeutics Pipeline Market H1 2015 Review Report Available at RnRMarketResearch.com
PRWeb - Sat Feb 14, 1:30AM CST
The report "Onychomycosis (Tinea Unguium) - Pipeline Review, H1 2015″ provides comprehensive information on the therapeutic development for Onychomycosis (Tinea Unguium). Onychomycosis (Tinea Unguium) is a fungal illness of the nails. It is the most common nail disease in adults. It is spread through direct contact with the yeast. Onychomycosis is caused by thickened nail, ragged nail, unsightly nail and pain in the nail. The report strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Complete report is available @ http://www.rnrmarketresearch.com/onychomycosi...eport.html .
ANAC: 99.06 (-0.14)
(0)
(0)Scroll down for more posts ▼